The First Topical Muscle Relaxant
Discover the future of anti-spasmodics through our innovative products
The First Topical Muscle Relaxant
Discover the future of anti-spasmodics through our innovative products
Our Purpose
Muscle pain and spasms impact nearly 2 billion people globally, but no FDA-approved topical muscle relaxant exists. Current products only treat symptoms, not the root cause.
Prima Innovations is developing PI-111, the first true topical muscle relaxant. Targeting a $3 billion+ market, PI-111 provides a safer, more effective solution than existing CNS-targeted treatments with significant side effects.
By directly addressing muscle spasms, PI-111 revolutionizes muscle pain relief for billions worldwide.
Our Innovation
PRIMA INNOVATIONS has the answer in PI-111, a topical muscle relaxant with tremendous applications for one and all, that directly targets the muscle spasm, relieving the associated pain and discomfort without the CNS side-effects seen with currently available oral meds like
Cyclobenzaprine (Flexeril©).
Common Reasons for muscle spasms:
• Stress
• Overuse of particular muscle group
• Repetitive strain injuries
• Sprains and strains
• Excessive physical activity
• Infections
• Neuro-degenerative diseases like ALS
• Chemotherapy spasms
Prima Innovation's strategy is to develop PI-111 to the point where it's attractive to a pharmaceutical company to in-license.
Our Impact
No Muscle Relaxant Tablets or Capsules for localized Muscle Spasm
We are proud of the impact that our products have had on patient care. Our products have been used to treat chronic muscle spasms . We are committed to continuing to develop innovative solutions that improve patient outcomes.
Funding Proposal and Regulatory Path
Prima seeks $2.0 million to progress its novel topical muscle relaxant, PI-111, towards an Investigational New Drug (IND) filing via the 505(b)(2) pathway. Funds will support:
- Mechanism of action studies
- Formulation and manufacturing development
- Analytical and stability testing
- IND-enabling toxicology studies
After IND filing, an additional $5-7 million is targeted for Phase I/II clinical trials.
The total FDA approval program is estimated at $25 million. However, Prima aims to exit after Phase I/II, positioning PI-111 for commercialization by a strategic partner in this multi-billion dollar market opportunity.